WallStSmart

ACADIA Pharmaceuticals Inc (ACAD)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ACADIA Pharmaceuticals Inc generates 147508% more annual revenue ($1.10B vs $742,000). ACAD leads profitability with a 34.3% profit margin vs 0.0%. ACAD earns a higher WallStSmart Score of 54/100 (C-).

ACAD

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 7.0Value: 5.7Quality: 7.8
Piotroski: 4/9

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACAD5 strengths · Avg: 9.6/10
P/E RatioValuation
9.5x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.1%10/10

Every $100 of equity generates 30 in profit

Profit MarginProfitability
34.3%10/10

Keeps 34 of every $100 in revenue as profit

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ACAD3 concerns · Avg: 1.7/10
PEG RatioValuation
50.862/10

Expensive relative to growth rate

EPS GrowthGrowth
-81.8%2/10

Earnings declined 81.8%

Operating MarginProfitability
-1.7%1/10

Operating margin of -1.7%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ACAD

The strongest argument for ACAD centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 34.3% and operating margin at -1.7%.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ACAD

The primary concerns for ACAD are PEG Ratio, EPS Growth, Operating Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ACAD profiles as a mature stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ACAD is growing revenue faster at 9.7% — sustainability is the question.

ACAD generates stronger free cash flow (29M), providing more financial flexibility.

Bottom Line

ACAD scores higher overall (54/100 vs 24/100), backed by strong 34.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ACADIA Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?